2017
Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
Haddad R, Seiwert T, Chow L, Gupta S, Weiss J, Gluck I, Eder J, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Huang L, Ayers M, Mogg R, Cristescu R, Cheng J, Mehra R. Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2017, 35: 6009-6009. DOI: 10.1200/jco.2017.35.15_suppl.6009.Peer-Reviewed Original ResearchNeoantigen loadWhole-exome sequencingPD-1/EBV statusObjective responseGene expression profilesNeck squamous cell carcinomaAnti CTLA-4PD-1 therapyIndependent predictive valueSquamous cell carcinomaCentral immune toleranceMutational loadFFPE tumor specimensSomatic mutational loadGEP scoreL1 immunotherapyL1 therapyClinical outcomesImmune toleranceSelect tumorsCell carcinomaCTLA-4Combined cohortViral status
2014
Projections: Novel Therapies for HPV-Negative Cancers of the Head and Neck
Burtness B. Projections: Novel Therapies for HPV-Negative Cancers of the Head and Neck. Current Cancer Research 2014, 343-359. DOI: 10.1007/978-1-4614-8815-6_17.Peer-Reviewed Original ResearchHuman papillomavirusNeck cancerNovel therapiesHPV-negative cancersPD-1 inhibitorsIntensification of therapyHPV-negative headReceptor c-MetAdvanced headImmune suppressionCTLA-4Larynx cancerC-MetCurrent trialCancerTherapyMolecular targetsErbB/Radiation techniquesFamily membersBiomolecular profileHeadPatientsPapillomavirusNeck